ReviewBlood2018
Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation.
Review in Blood, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed.
- Evaluating the safety and feasibility of prophylactic third-party NK cell administration in high-risk AML patients post-HSCT.BMC cancer · 2025Trial
- Reconstitution of Natural Killer cells after allogeneic hematopoietic stem cell transplantation is facilitated by Huiyang-Guben decoction through activating the Smad7/Stat3 signal pathway.Molecular and cellular biochemistry · 2024Trial
- Improving selection of patients with metastatic colorectal cancer to benefit from cetuximab based on KIR genotypes.Journal for immunotherapy of cancer · 2021Trial
- Synergistic immune interactions between T cells and natural killer cells in allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: current status and future directions.Annals of medicine · 2026Review
- Article
- Natural killer cells in kidney immune surveillance, injury and fibrosis.Nature reviews. Nephrology · 2026Review
- Beyond KIR and NKG2A blockade: reprogramming NK-cell immunity in solid tumors.Frontiers in cell and developmental biology · 2026Review
- High IL-10 levels during CRS are negatively associated with NK-cell recovery after CAR-T cell therapy.Clinical & translational immunology · 2026Article
- HOPX is required for the generation of umbilical cord blood-derived memory-like NK cells induced by three cytokines.Frontiers in immunology · 2026Article
- Contrasting relapse rate associated with the absence of HLA-A3/A11 in T cell-replete haploidentical transplantation.Frontiers in immunology · 2026Article
- Unraveling the Interplay Between Alcohol, Immunity, and Gastric Cancer: A Genomic Approach.Food science & nutrition · 2025Article
- The Association Between Cytomegalovirus Infection and Increased Leukemia Incidence: A Retrospective Matched Cohort.Cureus · 2025Article
- Targeting lactylation reinforces NK cell cytotoxicity within the tumor microenvironment.Nature immunology · 2025Article
- Review
- Overexpressing natural killer group 2 member A drives natural killer cell exhaustion in relapsed acute myeloid leukemia.Signal transduction and targeted therapy · 2025Article
- Prediction and effect on relapse of natural killer cell alloreactivity based on KIR-HLA interactions in pediatric haploidentical transplantation with anti-thymoglobulin.Frontiers in immunology · 2025Article
- Review
- A "Prime and Expand" strategy using the multifunctional fusion proteins to generate memory-like NK cells for cell therapy.Cancer immunology, immunotherapy : CII · 2024Article
- Identification of immune-related prognostic biomarkers in triple-negative breast cancer.Translational cancer research · 2024Article
- HLA Haplotypes and Relapse After Hematopoietic Cell Transplantation.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Article
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Natural killer (NK) cells are lymphocytes of innate immunity that respond to virus infected and tumor cells. After allogeneic transplantation, NK cells are the first reconstituting lymphocytes, but are dysfunctional. Manipulating this first wave of lymphocytes could be instrumental in reducing the 40% relapse rate following transplantation with reduced-intensity conditioning. NK cells express numerous activating and inhibitory receptors. Some recognize classical or nonclassical HLA class I ligands, others recognize class I-like ligands or unrelated ligands. Dominant in the NK-cell transplant literature are killer cell immunoglobulin-like receptors (KIRs), encoded on chromosome 19q. Inhibitory KIR recognition of the cognate HLA class I ligand is responsible for NK-cell education, which makes them tolerant of healthy cells, but responsive to unhealthy cells having reduced expression of HLA class I.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.